BRCA2 Protein

• 

  Subject Areas on Research

  • A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer. 
  • A review of hereditary breast cancer: from screening to risk factor modification. 
  • A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. 
  • Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations. 
  • Arabidopsis BRCA2 and RAD51 proteins are specifically involved in defense gene transcription during plant immune responses. 
  • Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches. 
  • Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. 
  • Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: A meta-analysis. 
  • BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines. 
  • BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer. 
  • BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. 
  • BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. 
  • BRCA2 monoclonal antibodies react with differentiating epithelium. 
  • BRCA2 mutations in primary breast and ovarian cancers. 
  • Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence? 
  • Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations. 
  • Cell cycle control of BRCA2. 
  • Comparing Coordinated Versus Sequential Salpingo-Oophorectomy for BRCA1 and BRCA2 Mutation Carriers With Breast Cancer. 
  • Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and "BRCAness" Mutations. 
  • Component-wise gradient boosting and false discovery control in survival analysis with high-dimensional covariates. 
  • Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models. 
  • Consortium analysis of 7 candidate SNPs for ovarian cancer. 
  • Cost Comparison of Genetic Testing Strategies in Women With Epithelial Ovarian Cancer. 
  • Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer. 
  • Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer. 
  • Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery. 
  • Estimating the number of potential family members eligible for BRCA1 and BRCA2 mutation testing in a "Traceback" approach. 
  • Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. 
  • Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. 
  • Exploiting DNA damage without repair: The activity of platinum chemotherapy in BRCA-mutated prostate cancers. 
  • Facilitated cascade testing (FaCT): a randomized controlled trial. 
  • Familial breast-ovarian cancer syndromes: BRCA1 and BRCA2. 
  • Genetic susceptibility testing and prophylactic oophorectomy. 
  • Genetic/familial high-risk assessment: breast and ovarian. 
  • Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. 
  • Germline Genetic Testing: What the Breast Surgeon Needs to Know. 
  • Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. 
  • Germline genetic variants in men with prostate cancer and one or more additional cancers. 
  • Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. 
  • Identification of six new susceptibility loci for invasive epithelial ovarian cancer. 
  • Identification of the breast cancer susceptibility gene BRCA2. 
  • Impact of Patents and Licensing Practices on Access to Genetic Testing for Inherited Susceptibility to Cancer: Comparing Breast and Ovarian Cancers to Colon Cancers 
  • Improving indel detection specificity of the Ion Torrent PGM benchtop sequencer. 
  • Isolation and initial characterization of the BRCA2 promoter. 
  • Managing hereditary ovarian cancer risk. 
  • Molecular evolution of a Drosophila homolog of human BRCA2. 
  • Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. 
  • Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. 
  • Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in BRCA1 and BRCA2. 
  • Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ. 
  • Posttraumatic stress associated with cancer history and BRCA1/2 genetic testing. 
  • Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. 
  • Rare germline mutations in African American men diagnosed with early-onset prostate cancer. 
  • Rare loss of function variants in candidate genes and risk of colorectal cancer. 
  • Reactive lymphoid hyperplasia in association with 22q11.2 deletion syndrome and a BRCA2 mutation. 
  • Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer. 
  • Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer. 
  • Risk factors for ovarian cancers with and without microsatellite instability. 
  • Screening for familial and hereditary prostate cancer. 
  • Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer. 
  • Survival Benefit of Germline BRCA Mutation is Associated with Residual Disease in Ovarian Cancer. 
  • THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors. 
  • Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study. 
  • The genetic attributable risk of breast and ovarian cancer. 
  • Thymic model for examining BRCA2 expression and function. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Moorman, Patricia Gripka, Professor Emeritus in Family Medicine and Community Health, Duke Cancer Institute